Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Hyperfine (HYPR) Change in Cash (2021 - 2026)

Hyperfine posted quarterly Change in Cash of $5.2 million for Q1 2026, up 226.5% year-on-year from $1.6 million in Q1 2025, and down 62.63% on a QoQ basis from $14.0 million in Q4 2025.

Hyperfine (HYPR) has 6 years of Change in Cash data on file, last reported at $5.2 million in Q1 2026.

  • For the quarter ending Q1 2026, Change in Cash rose 226.5% year-over-year to $5.2 million; the trailing twelve-month figure through Mar 2026 stood at $7.7 million (up 126.1% YoY), and the FY2025 full-year result was -$1.6 million, up 95.72% from the prior year.
  • Change in Cash for Q1 2026 stood at $5.2 million, down from $14.0 million in the prior quarter.
  • Across five years, Change in Cash topped out at $14.0 million in Q4 2025 and bottomed at -$27.6 million in Q1 2022.
  • The 5-year median for Change in Cash is -$9.4 million (2024), against an average of -$8.8 million.
  • The widest annual swing landed in 2022, when Change in Cash plunged 217.16%; it then jumped 268.6% in 2025.
  • A 5-year view of Change in Cash shows it stood at -$15.5 million in 2022, then jumped by 34.39% to -$10.2 million in 2023, then climbed by 18.26% to -$8.3 million in 2024, then surged by 268.6% to $14.0 million in 2025, then sank by 62.63% to $5.2 million in 2026.
  • The last three Change in Cash figures came in at $5.2 million (Q1 2026), $14.0 million (Q4 2025), and -$3.5 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Cash (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -1.72 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -1.13 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -136.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -504.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -492.00 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 199.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -2.23 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 15.90 Mn
10 Hyperfine 149.47 Mn 108.20 Mn 1.98 Mn 5.24 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 5.24 Mn
Dec 31, 2025 14.01 Mn
Sep 30, 2025 -3.55 Mn
Jun 30, 2025 -7.96 Mn
Mar 31, 2025 -4.14 Mn
Dec 31, 2024 -8.31 Mn
Sep 30, 2024 -7.83 Mn
Jun 30, 2024 -9.40 Mn
Mar 31, 2024 -12.60 Mn
Dec 31, 2023 -10.17 Mn
Sep 30, 2023 -8.95 Mn
Jun 30, 2023 -9.82 Mn
Mar 31, 2023 -13.50 Mn
Dec 31, 2022 -15.50 Mn
Sep 30, 2022 -12.97 Mn
Jun 30, 2022 -16.86 Mn
Mar 31, 2022 -27.60 Mn
Dec 31, 2021 122.22 Mn
Sep 30, 2021 -9.74 Mn
Jun 30, 2021 -9.16 Mn
Mar 31, 2021 23.55 Mn